These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14650836)

  • 1. Novel therapies for renal cell carcinoma.
    Syed S; Tolcher AW
    Cancer Treat Res; 2003; 116():227-38. PubMed ID: 14650836
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
    Schrader AJ; Varga Z; Pfoertner S; Goelden U; Buer J; Hofmann R
    BJU Int; 2006 Mar; 97(3):461-5. PubMed ID: 16469008
    [No Abstract]   [Full Text] [Related]  

  • 3. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-angiogenic therapy in the treatment of advanced renal cell cancer.
    Board RE; Thistlethwaite FC; Hawkins RE
    Cancer Treat Rev; 2007 Feb; 33(1):1-8. PubMed ID: 17071006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF therapy for renal cell carcinoma.
    Escudier B
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):530-1. PubMed ID: 17679926
    [No Abstract]   [Full Text] [Related]  

  • 7. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
    Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive value of loci in VEGF pathway genes in bevacizumab treatment.
    Moroni M
    Lancet Oncol; 2012 Jul; 13(7):659-60. PubMed ID: 22608782
    [No Abstract]   [Full Text] [Related]  

  • 9. Are we ready for the 10% solution?
    Chen HX; Rubinstein LV; Shankar LK; Abrams JS
    Oncologist; 2014 May; 19(5):439-40. PubMed ID: 24755462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 12. VEGF inhibitors in renal cell carcinoma.
    Vachhani P; George S
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):1016-1028. PubMed ID: 28212363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
    Escudier B; Staehler M
    Eur Urol; 2018 Jan; 73(1):1-3. PubMed ID: 28890247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of body composition on clinical outcomes in metastatic renal cell cancer.
    Tang PA; Heng DY; Choueiri TK
    Oncologist; 2011; 16(11):1484-6. PubMed ID: 22020214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.
    Caro J; Morales E; Gutierrez E; Ruilope LM; Praga M
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):215-6. PubMed ID: 23458595
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 20. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.